echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Two Qilu injections have been reviewed!

    Two Qilu injections have been reviewed!

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On May 10, the NMPA official website showed that Qilu Pharmaceutical's Decitabine for Injection and Cefminox Sodium for Injection passed the consistency evaluation.


    Cefminox is a cephalosporin derivative, which belongs to the second generation of cephalosporins, which has the characteristics of broad antibacterial spectrum, strong bactericidal power, and multiple indications.


    Decitabine is a specific inhibitor of deoxyribonucleic acid methylation.


    Decitabine for injection is the fifth batch of varieties to be collected.


    Up to now, Qilu Pharmaceutical has 68 varieties (121 product regulations) passed/deemed to have passed the consistency evaluation, of which 34 varieties are the first domestic ones to have passed the evaluation, and 21 varieties are injections.


    Among the 60 varieties collected in the fifth batch, Qilu Pharmaceutical has 11 over-rated varieties selected, including oxaliplatin injection, isosorbide mononitrate sustained-release tablets, docetaxel injection, saxagliptin tablets, Fasudil Hydrochloride Injection, Palonosetron Hydrochloride Injection, Ceftriaxone Sodium for Injection, Ceftazidime for Injection, Gemcitabine Hydrochloride for Injection, Decitabine Hydrochloride for Injection and Ropivacaine Hydrochloride Injection.


    Source: Mi Neiwang database, NMPA

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.